Organoheterocyclic compounds
Selleck Chemical LLC SC-560
SC-560 is a highly selective COX-1 inhibitor with IC50 of 9 nM compared with the IC50 of 6 3 M for COX-2 nearly 1 000-fold higher than with COX-1
Selleck Chemical LLC SC-560
SC-560 is a highly selective COX-1 inhibitor with IC50 of 9 nM compared with the IC50 of 6 3 M for COX-2 nearly 1 000-fold higher than with COX-1
TARGETMOL CHEMICALS INC SC-75416 1MG
Also available in 5 mg, 10 mg, 25 mg, 50 mg and bulk. Please contact Fisher for quotes. SC-75416 is a selective COX-2 inhibitor for the study of pain. Purity 98.67%
TARGETMOL CHEMICALS INC SC-560 25MG
Also available in 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg and bulk. Please contact Fisher for quotes. SC-560 is a member of the diaryl heterocycle class of cyclooxygenase (COX) inhibitors. Purity 99.39%
TARGETMOL CHEMICALS INC SC-26196 10MG
Also available in 1 mg 2 mg 5 mg 25 mg 50 mg 100 mg and bulk. Please contact Fisher for quotes. SC-26196 is an orally active inhibitor of Delta6 desaturase (D6D) with IC50 of 0.2 uM in a rat liver microsomal assay with antiinflammatory properties. purity: 99%
Selleck Chemical LLC SC-58125-E0789-5MG
SC-58125 is a potent and selective inhibitor of human cyclooxygenase 2 (hCOX-2) and triple mutant of hCOX-2 with an IC50 of 0 04 M and 1 M respectively
Selleck Chemical LLC SC-514 S4907-10mg
SC-514 (GK 01140) is an orally active ATP-competitive IKK-2 inhibitor with IC50 of 3-12 M blocks NF- B-dependent gene expression does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases
Apexbio Technology LLC SC 26196 218136-59-5 50mg
SC 26196 is a small-molecule inhibitor targeting Delta6-desaturase (D6D FADS2) It is designed to inhibit D6D an enzyme catalyzing the desaturation of linoleic and -linolenic acids into longer-chain polyunsaturated fatty acids thereby modulating fatty acid metabolic pathways SC 26196 exerts its biological activity primarily through inhibition of D6D In rat liver microsome assays SC 26196 demonstrates inhibitory activity with an IC50 value of approximately 0 2 M Based on these pharmacological properties SC 26196 holds research potential in the regulation of lipid metabolism and the study of inflammatory processes in metabolic and inflammation-related disease models
Apexbio Technology LLC SC 26196 218136-59-5 10mg
SC 26196 is a small-molecule inhibitor targeting Delta6-desaturase (D6D FADS2) It is designed to inhibit D6D an enzyme catalyzing the desaturation of linoleic and -linolenic acids into longer-chain polyunsaturated fatty acids thereby modulating fatty acid metabolic pathways SC 26196 exerts its biological activity primarily through inhibition of D6D In rat liver microsome assays SC 26196 demonstrates inhibitory activity with an IC50 value of approximately 0 2 M Based on these pharmacological properties SC 26196 holds research potential in the regulation of lipid metabolism and the study of inflammatory processes in metabolic and inflammation-related disease models
Apexbio Technology LLC SC 560 188817-13-2 5mg
SC 560 (CAS 188817-13-2) is a selective inhibitor of cyclooxygenase-1 (COX-1) exhibiting an IC50 of 0 009 M for COX-1 and 6 3 M for COX-2 By preferentially blocking COX-1 activity SC 560 impedes the conversion of arachidonic acid to prostaglandins such as thromboxane and PGE2 In vitro studies demonstrate that SC 560 suppresses COX-1-derived prostaglandin generation in a concentration-dependent manner inhibits cellular proliferation and induces apoptosis In vivo administration results in complete inhibition of COX-1-mediated thromboxane B2 and PGE2 production and attenuation of tumor growth in ovarian epithelial cancer models SC 560 serves as a valuable tool for investigating COX-1 s roles in inflammation pain and tumorigenesis
Apexbio Technology LLC SC 560 188817-13-2 10mg
SC 560 (CAS 188817-13-2) is a selective inhibitor of cyclooxygenase-1 (COX-1) exhibiting an IC50 of 0 009 M for COX-1 and 6 3 M for COX-2 By preferentially blocking COX-1 activity SC 560 impedes the conversion of arachidonic acid to prostaglandins such as thromboxane and PGE2 In vitro studies demonstrate that SC 560 suppresses COX-1-derived prostaglandin generation in a concentration-dependent manner inhibits cellular proliferation and induces apoptosis In vivo administration results in complete inhibition of COX-1-mediated thromboxane B2 and PGE2 production and attenuation of tumor growth in ovarian epithelial cancer models SC 560 serves as a valuable tool for investigating COX-1 s roles in inflammation pain and tumorigenesis
Apexbio Technology LLC SC-514 354812-17-2 10mg
SC-514 (CAS 354812-17-2) is a cell-permeable and selective inhibitor of I B kinase 2 (IKK-2) exhibiting an IC50 range of 3 12 M against recombinant human IKK-2 SC-514 acts in a reversible and ATP-competitive manner at the ATP-binding site of IKK-2 and also inhibits the activity of the native IKK complex While it is an ATP-competitive inhibitor at IKK-2 SC-514 displays non-competitive inhibition at the I B substrate site In cellular models SC-514 suppresses I B phosphorylation and degradation reduces nuclear translocation of NF- B subunit p65 and dose-dependently decreases the expression of NF- B-dependent genes such as IL-6 IL-8 and COX-2 It has been utilized in studies exploring inflammatory signaling and osteoclastogenesis
Apexbio Technology LLC SC 79 305834-79-1 50mg
SC 79 (CAS 305834-79-1) is a small-molecule activator of the serine/threonine kinase Akt (protein kinase B) a primary downstream effector in the phosphatidylinositol-3-phosphate signaling cascade known for its anti-apoptotic functions Identified through chemical genetic screening SC 79 binds specifically to Akt s PH domain promoting its activation in the cytosolic compartment independently of membrane translocation This activation facilitates Akt phosphorylation by upstream kinases enhancing cell survival Research indicates SC 79 confers protective effects in cellular assays and animal models of ischemic stroke suggesting potential therapeutic relevance across neurological research applications
Apexbio Technology LLC SC-9 102649-78-5 10mg
SC-9 (CAS 102649-78-5) is a small molecule modulator that functions as an activator of protein kinase C (PKC) a family of enzymes involved in regulating intracellular signaling pathways By enhancing PKC enzymatic activity SC-9 influences cellular processes such as differentiation proliferation and survival This compound is frequently utilized in biomedical research to investigate the roles of PKC in various physiological and pathological contexts supporting studies aimed at elucidating disease mechanisms and informing the development of novel therapeutic approaches
Apexbio Technology LLC SC 560 188817-13-2 25mg
SC 560 (CAS 188817-13-2) is a selective inhibitor of cyclooxygenase-1 (COX-1) exhibiting an IC50 of 0 009 M for COX-1 and 6 3 M for COX-2 By preferentially blocking COX-1 activity SC 560 impedes the conversion of arachidonic acid to prostaglandins such as thromboxane and PGE2 In vitro studies demonstrate that SC 560 suppresses COX-1-derived prostaglandin generation in a concentration-dependent manner inhibits cellular proliferation and induces apoptosis In vivo administration results in complete inhibition of COX-1-mediated thromboxane B2 and PGE2 production and attenuation of tumor growth in ovarian epithelial cancer models SC 560 serves as a valuable tool for investigating COX-1 s roles in inflammation pain and tumorigenesis